Retatrutide MASH/Liver Trial: SYNERGY-Outcomes Preview

The SYNERGY-Outcomes trial for retatrutide and MASH (metabolic-associated steatohepatitis) represents one of the most promising applications of the triple-agonist drug. Phase 2 data showed retatrutide reduced liver fat content by up to 86% (Jastreboff et al., NEJM 2023) — a result so dramatic that it exceeded every other medication ever tested for fatty liver disease. The glucagon receptor component of retatrutide directly drives hepatic fat oxidation, making this drug uniquely suited for liver disease treatment. The SYNERGY trial will determine if this liver fat reduction translates to actual reversal of liver inflammation and fibrosis.

The MASH Crisis

MASH is quietly becoming one of the biggest health crises in the developed world:

• 100 million Americans have some form of fatty liver disease (NAFLD/MAFLD)
• 16 million have MASH specifically — the inflammatory form that causes liver damage
• Leading cause of liver transplantation in the coming decade
• No cure: Until recently, no FDA-approved drugs specifically targeted MASH
• Silent disease: Most patients are undiagnosed because MASH is often asymptomatic until severe damage occurs

The only approved treatment (resmetirom/Rezdiffra) targets thyroid hormone receptors. Retatrutide takes an entirely different approach — and the Phase 2 liver fat data suggests it could be dramatically more effective.

Why Glucagon Is Key for Liver Fat

Retatrutide's remarkable liver fat reduction stems primarily from the glucagon receptor component:

• Hepatic fat oxidation: Glucagon activates enzymes in the liver that break down stored fat for energy
• Reduced lipogenesis: Glucagon signaling reduces the liver's production of new fat
• Improved fat export: Enhanced VLDL secretion helps clear fat from the liver
• Weight loss amplification: The overall 24%+ weight loss reduces the fat supply reaching the liver

Single-agonist drugs (semaglutide) reduce liver fat modestly through weight loss alone. Dual agonists (tirzepatide) are better. But retatrutide's glucagon-specific mechanism attacks liver fat directly, producing the 86% reduction that is unprecedented in liver disease pharmacology.

Phase 2 Liver Data

SYNERGY-Outcomes Trial Design

• Population: Adults with biopsy-confirmed MASH with fibrosis stage F2-F3
• Primary endpoints: MASH resolution without worsening fibrosis; fibrosis improvement by at least one stage
• Key secondary endpoints: Liver fat change (MRI), liver enzyme changes, progression to cirrhosis
• Requires liver biopsies: Before and after treatment to confirm histological improvement
• Duration: 52-72 weeks of treatment

Implications for 100 Million Americans

If SYNERGY demonstrates that retatrutide resolves MASH and improves fibrosis, the implications extend far beyond the trial:

• Dual-purpose treatment: A single drug that addresses both obesity and liver disease — two of the most common chronic conditions
• Liver transplant prevention: Reversing fibrosis before it progresses to cirrhosis could prevent thousands of liver transplants
• Screening revolution: An effective treatment would justify widespread MASH screening, catching millions of undiagnosed cases
• Market impact: The MASH drug market is projected to exceed $35 billion, making this a significant commercial opportunity for Eli Lilly

Start Protecting Your Liver Today

Current GLP-1 medications also reduce liver fat. Through TRIMI:

• Compounded semaglutide: $99/month
• Compounded tirzepatide: $125/month

Learn more about how to get started.